Walleye Capital
CERO

Walleye Capital’s CERo Therapeutics CERO Stock Holding History

Walleye Capital’s Portfolio CERO Stock Details CERO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-24
Closed -$527K – 5980
2023
Q4 		$527K Hold
24
– – ﹤0.01% 2910
2023
Q3 		$521K Hold
24
– – ﹤0.01% 2791
2023
Q2 		$523K Hold
24
– – ﹤0.01% 2408
2023
Q1 		$512K Hold
24
– – 0.01% 1699
2022
Q4 		$492K Buy
+24
New +$489K 0.01% 1461

Other funds holding CERO

AVM
Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return
HH
HSG Holding Na, Hong Kong $1.62B AUM 5.91% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
BC
Birchview Capital Burlington, Vermont $176M AUM 95.04% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
KPWS
Kestra Private Wealth Services Austin, Texas $9.1B AUM 32.09% 1-Year Est. Return
PA
Pineridge Advisors St. Charles, Missouri $350M AUM 6.38% 1-Year Est. Return
FIA
FNY Investment Advisers New York $278M AUM 98.99% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Walleye Capital's CERO Position: Q1 2024 in Review

Walleye Capital sold out of CERo Therapeutics (CERO) in Q1 2024, closing a stake of 24 shares — an estimated $527K sold.

Walleye Capital first reported a position in CERO in Q4 2022 and held it in 5 quarters. The position peaked at $527K in Q4 2023. 7 funds tracked by Wall St. Rank hold CERO as of Q1 2024.

  • Walleye Capital reported no remaining CERo Therapeutics position as of Q1 2024 after selling out during the quarter.
  • Walleye Capital sold 24 CERo Therapeutics shares in Q1 2024, an estimated $527K.
  • Walleye Capital first reported a position in CERo Therapeutics in Q4 2022 and held it in 5 quarters.
  • Walleye Capital's CERo Therapeutics position peaked at $527K in Q4 2023.
  • 7 funds tracked by Wall St. Rank held CERo Therapeutics as of Q1 2024.

Based on Walleye Capital's 13F filing for Q1 2024, filed 15 May 2024.